FDA approves Medtronic device for Parkinson's treatment
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain activity, potentially improving symptom control, according to a Feb. 24 news release from the company.
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...
Medtronic (NYSE:MDT), which has operations worldwide, is reportedly looking at adjusting its manufacturing footprint amid ...
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed ...
The latest health news reveals Medtronic's strategic response to U.S. tariffs, WHO's concerns on West Bank violence, mystery ...
4don MSN
Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback